Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents
Valentine W, Palmer A, Lammert M, Langer J, Brändle M. Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents. Clin Ther 2011; 33:1698-712.
Oct 21, 2011
Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents
Oct 21, 2011
Clin Ther 2011; 33:1698-712
Valentine William J, Palmer Andrew J, Lammert Morten, Langer Jakob, Brändle Michael
more
